Can GLP-1s cause hypoglycemia
The recent Semaglutide Cardiovascular Outcomes Trial (SOUL) reported that once-daily oral semaglutide (maximal dose, 14 mg), in addition to standard care, significantly reduces the risk of MACE in individuals with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, without an increase in the incidence of serious adverse events [6]
Animal treatment Mice were maintained and used according to the guidelines of the Committee on Animal Use and Care of Southeast University
M.CostallB.CoxA
Many providers, it says, suggest postponing treatment until breastfeeding concludes
Published research has examined its effects on melanogenesis, UV-induced DNA damage, and melanocyte proliferation in various experimental systems